What is the recommended intra‑procedural unfractionated heparin dosing and activated clotting time target for pulmonary vein isolation, how should chronic oral anticoagulation be managed before and after the ablation, and what are the alternatives for patients with heparin‑induced thrombocytopenia?

Intraprocedural Heparin Management for Pulmonary Vein Isolation

During pulmonary vein isolation, administer intravenous unfractionated heparin to achieve and maintain an activated clotting time (ACT) of 300-350 seconds, with initial dosing adjusted based on the patient's chronic oral anticoagulation regimen. 1

Initial Heparin Dosing Strategy

The initial heparin bolus must be tailored to the patient's baseline anticoagulation:

• Patients on warfarin (uninterrupted): 50-100 units/kg 2
• Patients on NOACs: 120-130 units/kg 3, 2
• Patients not anticoagulated: 75-100 units/kg 2

The higher dosing requirement for NOAC patients (120-130 units/kg) is critical because these patients consistently demonstrate lower initial ACT values and require more heparin to reach therapeutic targets compared to warfarin-treated patients. 4, 3 Specifically, patients on rivaroxaban and apixaban need approximately 171-172 units/kg total dose versus 140-157 units/kg for warfarin/dabigatran patients. 4

Following the initial bolus, start a continuous infusion at 10% of the bolus dose per hour (e.g., 1200 units/hour for a 100 kg patient who received 12,000 units bolus). 2

ACT Monitoring Protocol

• Measure ACT every 15 minutes until stable at target
• Target ACT: 300-350 seconds 1
• Administer additional heparin boluses if ACT falls below 300 seconds
• The same target ACT range applies regardless of whether patients are on warfarin or NOACs 1

Critical Pitfall: ACT Platform Variability

Be aware that ACT values differ substantially between measurement platforms (mean differences of 50-60 seconds or 15-25% discrepancy). 5 Hemochron devices typically read higher than Abbott i-STAT, with Medtronic ACT Plus intermediate. If your institution switches ACT platforms, you must recalibrate your heparin dosing protocols accordingly. 5

Chronic Oral Anticoagulation Management

Before Ablation

Administer the last NOAC dose 12 hours before the procedure start time, particularly when transseptal puncture is performed without intracardiac echocardiography guidance. 1 This approach balances adequate anticoagulation with procedural safety.

Alternative strategies exist:

• "Truly uninterrupted" approach: Last NOAC dose on the morning of the procedure (used in RE-CIRCUIT trial with dabigatran, where 41% underwent ablation within 4 hours of last dose) 1
• Short cessation: Last dose evening before procedure (used in VENTURE-AF with rivaroxaban) 1

Rule out left atrial thrombus before ablation if:

• Medication adherence is uncertain
• Last NOAC dose was >36 hours before procedure
• Patient has high thromboembolic risk (high CHA₂DS₂-VASc score) 1

After Ablation

Resume NOAC 3-5 hours after sheath removal once adequate hemostasis is established and pericardial effusion has been ruled out. 1

Heparin-Induced Thrombocytopenia Alternatives

For patients with confirmed HIT requiring cardiac procedures:

First-Line Alternative: Bivalirudin

Bivalirudin is the preferred alternative anticoagulant for patients with HIT undergoing cardiac procedures. 6

Dosing for cardiac procedures:

• IV bolus: 0.75-1 mg/kg
• Continuous infusion: 1.75-2.5 mg/kg/hour during procedure
• Target ACT: >300 seconds (if ACT <300 seconds, increase infusion by 0.25 mg/kg/hour) 6
• Stop infusion 15 minutes before anticipated end of procedure
• Contraindicated in severe renal failure (CrCl <30 mL/min) 6

Second-Line: Antiplatelet Agent + Heparin Strategy

This approach uses platelet inhibition before heparin administration to prevent HIT antibody-mediated platelet activation:

Tirofiban protocol:

• IV bolus: 10 mcg/kg
• Wait 15 minutes, then administer standard heparin
• Continuous infusion: 0.15 mcg/kg/min
• Stop 1 hour before end of bypass 6, 7
• Limitation: Platelet function recovery takes 8 hours, increasing bleeding risk 6

Cangrelor protocol (preferred over tirofiban due to rapid offset):

• IV bolus: 30 mcg/kg, 10 minutes before heparin
• Continuous infusion: 4 mcg/kg/min
• Stop 5 minutes before end of procedure 6
• Platelet function recovers within 3-6 minutes 6

Third-Line: Argatroban

Argatroban is an option but has limited experience and higher complication rates (clots in cardiotomy reservoir, bleeding) compared to bivalirudin. 6 It is not recommended as first-line for cardiac procedures.

Important Considerations for HIT Management

• Avoid pericardial blood aspiration when using bivalirudin (enzymatic degradation by thrombin causes unpredictable anticoagulation) 6
• All heparin must be strictly avoided (including catheter flushes, heparin locks) when using the antiplatelet + heparin strategy 6
• For pregnancy with HIT: use danaparoid or fondaparinux 6